Edition:
United States

Profile: Osiris Therapeutics Inc (OSIR.OQ)

OSIR.OQ on NASDAQ Stock Exchange Global Market

5.61USD
29 Apr 2016
Change (% chg)

$-0.26 (-4.43%)
Prev Close
$5.87
Open
$5.84
Day's High
$5.88
Day's Low
$5.56
Volume
20,678
Avg. Vol
68,312
52-wk High
$23.32
52-wk Low
$3.55

Search Stocks

Osiris Therapeutics, Inc., incorporated on March 30, 2010, is a medical products company. The Company is focused on developing and marketing products in regenerative medicine, including bioengineering, stem cell research and viable tissue based products. The Company's offers products in orthopedics, sports medicine and wound care, including Cartiform, BIO4 and Grafix.

Cartiform is a viable chondral allograft containing viable chondrocytes, chondrogenic growth factors, and extracellular matrix proteins within the intact architecture of healthy hyaline cartilage. Cartiform promotes articular cartilage repair to treat focal chondral defects. Cartiform combines the safety and proven success of fresh osteochondral allografts with ease of use resulting from Osiris' cryopreservation technology. Cartiform can be implanted in a single step procedure.

BIO4 is a bone allograft that contains both viable cells and growth factors. It is a safe alternative to autograft that minimizes the potential for harvest site co-morbidities. BIO4 is composed of a structural extracellular matrix, osteogenic and angiogenic growth factors, endogenous mesenchymal stem cells and osteoblasts. It possesses osteoconductive, osteoinductive, osteogenic and angiogenic properties that are required for bone repair and regeneration. It is ready-to-use out of the package. BIO4 was originally branded as OvationOS.

Grafix is a cryopreserved placental membrane that preserves the native properties and inherent functionality of the tissue. The flexible, conforming three-dimensional matrix is designed for direct application to hard-to-treat acute and chronic wounds, including but not limited to diabetic foot ulcers, venous leg ulcers and burns. Grafix is produced by utilizing Osiris' BioSmart Intelligent Tissue Processing, which retains the extracellular matrix, growth factors, and endogenous neonatal mesenchymal stem cells, fibroblasts and epithelial cells of the native tissue.

The Company competes with Organogenesis and MiMedx.

Company Address

Osiris Therapeutics Inc

7015 Albert Einstein Drive
COLUMBIA   MD   21046
P: +1443.5451800
F: +1443.5451701

Company Web Links

Search Stocks